Impact de l’utilisation de l’agomélatine sur la consommation d’hypnotiques

Sapinho, 2008, Mesure de l’épisode dépressif majeur en population générale : apports et limites des outils, BEH, 35–36, 314 Prise en charge des complications évolutives d’un épisode dépressif caractérisé de l’adulte/Recommandations. France: HAS; avril 2007. Loi no 2004-806 du 9 août 2004 relative à la politique de santé publique. no 4. JORF no 185: Texte no 4 (11 août 2004). Chan Chee, 2005 Monteleone, 2008, The circadian basis of mood disorders: recent developments and treatment implications, Eur Neuropsychopharmacol, 18, 701, 10.1016/j.euroneuro.2008.06.007 Dijk, 1995, Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans, J Neurosci, 15, 3526, 10.1523/JNEUROSCI.15-05-03526.1995 Résumé des caractéristiques du produit de Valdoxan® Agomélatine. Olie, 2007, Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder, Int J Neuropsychopharmacol, 10, 661 Kennedy, 2006, Placebo-controlled trial of agomelatine in the treatment of major depressive disorder, Eur Neuropsychopharmacol, 16, 93, 10.1016/j.euroneuro.2005.09.002 Goodwin, 2009, Agomelatine prevents relapse in patients with major depressive disorder, without evidence of a discontinuation syndrome, J Clin Psychiatry, 70, 1128, 10.4088/JCP.08m04548 Hale, 2010, Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study, Int Clin Psychopharmacol, 25, 305, 10.1097/YIC.0b013e32833a86aa Lemoine, 2007, Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double blind comparison with venlafaxine, J Clin Psychiatry, 68, 1723, 10.4088/JCP.v68n1112 Kasper, 2010, Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline, J Clin Psychiatry, 71, 109, 10.4088/JCP.09m05347blu Kräuchi, 1997, Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature, Am J Physiol, 272, R1178 Cajochen, 1997, Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis, Am J Physiol, 272, R1189 Leproult, 2005, Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men, Clin Endrocrinol, 63, 298, 10.1111/j.1365-2265.2005.02341.x Quera Salva, 2007, Major depressive disorder, sleep EEG and agomelatine: an open-label study, Int J Neuropsychopharmacol, 10, 691 Afssaps. État des lieux de la consommation des benzodiazépines en France. Janvier 2012. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2011. http://www.whocc.no/. Quera-Salva, 2011, Comparison of agomelatine and escitalopram on nighttime and daytime condition and efficacy in major depressive disorder patients, Int Clin Psychopharmacol, 26, 252, 10.1097/YIC.0b013e328349b117